Akari Therapeutics, Plc (NASDAQ:AKTX) Short Interest Up 94.6% in December

Akari Therapeutics, Plc (NASDAQ:AKTX) was the target of a significant increase in short interest in December. As of December 31st, there was short interest totalling 144,200 shares, an increase of 94.6% from the December 15th total of 74,100 shares. Based on an average daily trading volume, of 55,400 shares, the days-to-cover ratio is currently 2.6 days. Approximately 1.2% of the shares of the company are sold short.

Akari Therapeutics Trading Up 8.7 %

AKTX opened at $1.25 on Thursday. Akari Therapeutics has a 1-year low of $0.90 and a 1-year high of $4.40. The company has a 50 day simple moving average of $1.34 and a two-hundred day simple moving average of $2.56.

Wall Street Analysts Forecast Growth

Separately, StockNews.com assumed coverage on Akari Therapeutics in a research report on Monday. They set a “sell” rating on the stock.

Akari Therapeutics Company Profile

Akari Therapeutics, Plc, a clinical-stage biopharmaceutical company, focuses on developing advanced therapies for autoimmune and inflammatory diseases. Its lead product candidate is nomacopan, a second-generation complement inhibitor that prevents inflammatory and prothrombotic activities, including paroxysmal nocturnal hemoglobinuria, Guillain-Barré syndrome, hematopoietic stem cell transplant-associated thrombotic microangiopathy, and bullous pemphigoid, as well as pre-clinical program developing long-acting PASylated-nomacopan for treatment of geographic atrophy secondary to dry age-related macular degeneration.